Results 71 to 80 of about 1,302,201 (345)

Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

Frontiers in Psychology, 2020
BackgroundThe psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e ...
Maria Francesca Alvisi, Paola Dordoni, Tiziana Rancati, Barbara Avuzzi, Nicola Nicolai, Fabio Badenchini, Letizia De Luca, Tiziana Magnani, Cristina Marenghi, Julia Menichetti, Villa Silvia, Zollo Fabiana, Salvioni Roberto, Valdagni Riccardo, Valdagni Riccardo, Valdagni Riccardo, Bellardita Lara, the Prostate Cancer Multidisciplinary Clinic Working Group   +17 more
doaj   +1 more source

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology, 2019
PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer.
A. Armstrong, R. Szmulewitz, D. Petrylak, J. Holzbeierlein, A. Villers, A. Azad, A. Alcaraz, B. Alekseev, T. Iguchi, N. Shore, B. Rosbrook, J. Sugg, B. Baron, Lucy F. Chen, A. Stenzl   +14 more
semanticscholar   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

Molecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla, Jana R. Crespo, Saioa Garcia‐Longarte, Marta Fidalgo, Sara del Palacio, Natalia Martin‐Martin, Onintza Carlevaris, Ianire Astobiza, Sonia Fernández‐Ruiz, Marc Guiu, Laura Bárcena, Isabel Mendizabal, Ana M. Aransay, Mariona Graupera, Roger R. Gomis, Arkaitz Carracedo   +15 more
wiley   +1 more source

Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2019
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

Neoplasia: An International Journal for Oncology Research, 2001
BACKGROUND: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%.
Tobias Zellweger, Hideaki Miyake, Laura V. July, Majid Akbari, Satoshi Kiyama, Martin E. Gleave   +5 more
doaj   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Tumor-associated long non-coding RNAs show variable expression across diffuse gliomas and effect on cell growth upon silencing in glioblastoma

Scientific Reports
Long noncoding RNAs (lncRNAs) have been recently recognized as critical components of cancer biology linked to oncogenic processes. Certain lncRNAs are known to act as oncogenes, and the disease-specific expression of many lncRNAs makes them informative ...
Joonas Uusi-Mäkelä, Maria Kauppinen, Janne Seppälä, Serafiina Jaatinen, Birgitta Ryback, Tommi Rantapero, Alejandra Rodriguez-Martinez, Matti Nykter, Kirsi J. Rautajoki   +8 more
doaj   +1 more source

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

Prostate Cancer, 2011
Introduction. Concern regarding overtreatment of prostate cancer (CaP) is leading to increased attention on active surveillance (AS). This study examined CaP survivors on AS and compared secondary treatment patterns and overall survival by race/ethnicity.
Jennifer Cullen, Stephen A. Brassell, Yongmei Chen, Christopher Porter, James L'Esperance, Timothy Brand, David G. McLeod   +6 more
doaj   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

JAMA Oncology, 2019
Importance The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the ...
W. Abida, M. Cheng, J. Armenia, S. Middha, K. Autio, H. Vargas, D. Rathkopf, M. Morris, D. Danila, S. Slovin, E. Carbone, E. Barnett, Melanie A. Hullings, J. Hechtman, A. Zehir, J. Shia, P. Jonsson, Z. Stadler, P. Srinivasan, V. Laudone, V. Reuter, J. Wolchok, N. Socci, B. Taylor, M. Berger, P. Kantoff, C. Sawyers, N. Schultz, D. Solit, A. Gopalan, H. Scher   +30 more
semanticscholar   +1 more source